GHK-Cu in Australia

Copper-binding tripeptide (glycyl-L-histidyl-L-lysine:Cu²⁺). GHK-Cu is a tripeptide that occurs in nature and binds copper with high affinity. First isolated from human plasma in 1973, its concentration drops from around 200 ng/mL in young adults to roughly 80 ng/mL by age 60. Researchers study it across wound repair, collagen synthesis, hair follicle biology and gene-expression changes in aged tissue. The same molecule turns up at low levels in cosmetic serums; the research vial holds the pure copper complex.

Collagen and elastin synthesis: fibroblast stimulation and lysyl oxidase activity. Wound healing: closure rate and remodelling in animal and human wounds. Gene expression: wide transcriptional effects in aged and cancer cell lines. Hair follicle biology: follicle size and growth-phase markers. Antioxidant defence: sOD activation and inhibition of iron release. Animal wound studies and small human trials reported quicker closure and more collagen deposition. Controlled facial studies of topical GHK-Cu creams reported better skin thickness, elasticity and fine-line depth over 12 weeks. Hair studies show larger follicles in culture and in animal models. The bulk of the data is topical or in-vitro, with injectable research confined to preclinical work.

Twelve-week controlled facial studies reported greater skin thickness and density on ultrasound, better elasticity and shallower wrinkle depth on profilometry; wound studies reported quicker closure; follicle cultures showed larger follicles. The human evidence is topical.

Topical GHK-Cu is well tolerated across the published trials, with the odd case of mild irritation. No human safety data exist for injectable use; copper exposure from the peptide is on a microgram scale and bound.

In the published GHK-Cu research, the amounts used were 1 × 10⁻⁹ mol/L in cell culture, human dermal fibroblasts (Pollard JD et al. (2005)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies GHK-Cu for in-vitro research and does not give dosing guidance for people.

Cosmetic serums and creams at 0.01-0.1% are the form the human skin studies relied on. The vial is the unformulated copper complex for bench work and formulation development.

In skincare, 'copper peptides' usually means GHK-Cu, occasionally AHK-Cu; GHK-Cu is the one carrying the research record.

AHK-Cu is a separate copper tripeptide studied mostly for hair; GHK-Cu holds the wider skin and wound literature.

GLOW blends GHK-Cu with BPC-157 and TB-500 for combined skin and repair research.

Cosmetic serums carry GHK-Cu at low concentrations in a formulated base meant for the skin, and that is the form behind most of the human skin data. The lyophilised vial is the unformulated copper complex, supplied with a batch certificate on request and intended for laboratory study at concentrations a serum could never reach. Our topical-versus-injectable guide walks through the difference.

The published studies track skin thickness by ultrasound, elasticity by cutometer, wrinkle depth by profilometry, wound area, and follicle diameter in hair models. Our evidence guide lays out the endpoints and how large the reported changes were.

At topical concentrations as a cosmetic ingredient, yes, and it appears in registered cosmetics. Injectable or research-grade GHK-Cu, however, is not approved for human use in Australia. Peptide Aus supplies the vial for in-vitro research only.

Go with the 50mg vial for shorter cell-culture or topical-formulation work. The 100mg vial cuts the cost per milligram by roughly half for longer protocols.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

GHK-Cu is allowed in cosmetics at topical concentrations, yet no injectable or research-grade GHK-Cu product has approval for human use in Australia. Peptide Aus supplies the vial for in-vitro laboratory research only.

Directly from Peptide Aus, from Australian stock, in 2 vial sizes from $99.99 (50mg) to $149.99 (100mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.

It depends on the vial size: 50mg takes 3 mL, 100mg takes 3 mL. That gives 16.7 mg/mL, 33.3 mg/mL respectively. The reconstitution steps on this page and the calculator cover the rest.